In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, Myriad Genetics, Inc. used $8.3 million of cash from operations, up 39.0% from the same quarter a year earlier.
USD in millions, except per-share amounts and ratios. The percent under a figure is the change from the same quarter a year earlier.
| Line |
TTM
Jun 30, 2026
|
Q2 FY2026
Jun 30, 2026
|
Q1 FY2026
Mar 31, 2026
|
Q4 FY2025
Dec 31, 2025
|
Q3 FY2025
Sep 30, 2025
|
Q2 FY2025
Jun 30, 2025
|
Q1 FY2025
Mar 31, 2025
|
Q4 FY2024
Dec 31, 2024
|
Q3 FY2024
Sep 30, 2024
|
|---|---|---|---|---|---|---|---|---|---|
| Operating | |||||||||
| Depreciation and amortization |
50
-14.8%
|
12
-11.3%
|
12
-13.2%
|
13
-14.9%
|
13
-19.2%
|
14
-6.6%
|
14
-8.3%
|
15
-2.0%
|
16
+10.6%
|
| Stock-based compensation |
29
-34.0%
|
7
-32.7%
|
6
-31.6%
|
3
-74.3%
|
12
-1.6%
|
11
-26.2%
|
10
-20.8%
|
11
+4.8%
|
12
+6.9%
|
| Operating cash flow |
8
+134.1%
|
-8
+39.0%
|
-16
+3.7%
|
11
+60.6%
|
21
+2914.3%
|
-14
-623.1%
|
-16
+12.4%
|
7
+112.1%
|
1
+103.2%
|
| Investing | |||||||||
| Investing cash flow |
-22
-61.0%
|
-3
+53.6%
|
-6
+21.7%
|
-6
-1.7%
|
-6
-182.7%
|
-7
-7.8%
|
-8
-16.9%
|
-6
+50.8%
|
8
+400.0%
|
| Financing | |||||||||
| Financing cash flow |
47
+210.5%
|
2
-15.4%
|
-3
-122.1%
|
-8
-490.5%
|
56
+1912.9%
|
3
+8.3%
|
14
+254.5%
|
2
-98.3%
|
-3
-24.0%
|
| Change in cash | |||||||||
| Effect of exchange rate |
0
-91.7%
|
0
-83.3%
|
-0
-200.0%
|
0
+114.3%
|
0
-100.0%
|
1
+185.7%
|
0
+112.5%
|
-1
-200.0%
|
1
+300.0%
|
| Net change in cash |
33
+289.1%
|
-9
+46.8%
|
-25
-132.1%
|
-4
-266.7%
|
71
+726.7%
|
-17
-293.2%
|
-11
+69.1%
|
2
-96.2%
|
9
+131.0%
|
| Ratios | |||||||||
| Stock-based compensation to revenue |
3.56%
|
3.78%
|
3.24%
|
1.33%
|
5.93%
|
5.02%
|
4.85%
|
5.18%
|
5.81%
|
How these figures are calculated
Quarterly columns are single-quarter amounts. When a 10-Q reports only a year-to-date total, as cash flow statements do, the quarter is that total minus the previous quarter's year-to-date total. The fourth quarter is the annual report's full year minus the first nine months. A column marked YTD is a year-to-date total, shown when the earlier report needed for the single quarter is missing. USD in millions, except per-share amounts and ratios. Capital expenditures, debt repaid, dividends, and buybacks are positive amounts. Investing and financing cash flow keep the filing sign, so an outflow is negative. Free cash flow is operating cash flow minus capital expenditures. The first column is the trailing twelve months through the latest quarter. Returned to shareholders is dividends plus buybacks. Free cash flow margin, capital expenditures, and stock-based compensation are divided by revenue. Cash conversion is operating cash flow divided by net income. More on our methodology.
Company profile
- Industry
- In Vitro & In Vivo Diagnostic Substances (SIC 2835)
- Listed as
- MYGN (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Salt Lake City, UT
- SEC filer status
- Accelerated filer
- SEC CIK
- 899923
- Former names
- MYRIAD GENETICS INC (until Nov 5, 2026)
Other In Vitro & In Vivo Diagnostic Substances companies
- Idexx Laboratories Inc /DE IDXX
- Lantheus Holdings, Inc. LNTH
- Neogen Corp NEOG
- Celldex Therapeutics, Inc. CLDX
- Intellia Therapeutics, Inc. NTLA
- QuidelOrtho Corp QDEL
- Achieve Life Sciences, Inc. ACHV
- Alpha Teknova, Inc. TKNO
Source: SEC EDGAR filings. This is company-reported data, not investment advice.